N/A
Completed N=288
Study Evaluating Refacto For Pharmacovigilance
Source: ClinicalTrials.gov NCT00195442 ↗Enrolled (actual)
288
Serious AEs
49.0%
Results posted
Feb 2011
Primary outcomePrimary: Mean Number of Bleeding Episodes Per Patient Year — 13.41 episodes per year
Summary
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Number of Bleeding Episodes Per Patient Year |
13.41 | — |
| PRIMARY Mean Number of Bleeding-related Exposure Days Per Patient Year |
20.58 | — |
| PRIMARY Mean Number of Exposure Days Per Patient Year |
126.76 | — |
| SECONDARY Number of Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) |
668; 291 | — |
| SECONDARY Number of Participants With de Novo Inhibitor Formation |
7 | — |
| SECONDARY Mean Annual ReFacto Consumption Per Patient Year |
204509 | — |
| SECONDARY Number of Participants for Physicians' Assessment of Satisfaction With Treatment Success |
92; 73; 3; 1 | — |
| SECONDARY Number of Participants for Physicians' Assessment of Efficacy |
111; 111; 38; 9 | — |
| SECONDARY Number of Participants for Patients' Assessment of Efficacy |
103; 116; 35; 11; 4 | — |
| SECONDARY Number of Participants for Physicians' Assessment of Tolerance |
130; 137; 2 | — |
| SECONDARY Number of Participants for Patients' Assessment of Tolerance |
131; 132; 1; 1; 4 | — |
| SECONDARY Number of Participants for Physicians' Assessment of Handling of ReFacto |
109; 154; 6 | — |
| SECONDARY Number of Participants for Patients' Assessment of Handling of ReFacto |
99; 154; 11; 1; 4 | — |
| SECONDARY Number of Participants for Days of Sick Leave Per Month |
87; 32; 4; 8; 0; 36 | — |
Eligibility Criteria
Inclusion Criteria
- Proven diagnosis of Hemophilia A
Exclusion Criteria
- Contraindications according to Summary of Product Characteristics
Data sourced from ClinicalTrials.gov (NCT00195442). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.